Although the development of China's medical technology is slow, with the efforts and support of pharmaceutical companies and the national government, some blanks in medical technology have been gradually filled, which provides a driving force for the rapid and rapid development of the domestic pharmaceutical industry. Breaking the monopoly of medical technology is not an easy task. Once a pharmaceutical company succeeds, it will not only have a certain right to speak, but also bring benefits to enterprises and industries. Below, the author will take stock of the medical technology that has already or will break the monopoly in the near future.
Gan Li Pharmaceutical is expected to break the monopoly of the insulin market
The author expects that the current global insulin market and the domestic insulin market are basically interrupted by three multinational pharmaceutical companies, Novo Nordisk, Eli Lilly and Sanofi. In order to get rid of this situation, Gan Li Pharmaceutical has gradually caught up with the pace of research and development of multinational companies in recent years, and strives to compete with multinational pharmaceutical companies around the world.
According to relevant statistics, in 2015, Gan Li Pharmaceutical ranked third in China's third-generation insulin market share with 11.2% of the results, completing the 9% surpassing of Lilly. In terms of overseas markets, Gan Li Pharmaceutical's market performance is also relatively bright, and many stages of results have been achieved in developed countries such as Europe and the United States. Some insiders pointed out that if Gan Li Pharmaceutical successfully passed the approval of the US FDA, the successful implementation of insulin glargine in the United States would mean that domestic insulin is expected to further break the monopoly position of multinational pharmaceutical companies with high cost performance.
Chutian Technology breaks through the high-efficiency packaging equipment technology monopoly and participates in international competition
In the international technology and market competition, high-efficiency dispensing equipment is a high-tech, high-difficult, high-risk high-end equipment, with high technical thresholds, and the core technology has long been monopolized by international giants. The technical gap in the domestic industry in this field needs to be filled, and Chutian Technology has invested a lot of research and development funds and time to try to tackle the problem.
It is reported that through more than ten years of continuous research and research on production, education and research, Chutian Technology has realized the crushing control of high-speed transport of thin-walled medicine bottles, the precise loading control of small-dose medicaments, the on-line rapid detection and control of fine foreign bodies, and the development of 5 major Class 119 series of high-efficiency and high-precision packaging equipment, breaking the monopoly of technology, successfully achieving industrialization and participating in international competition.
After three years of hard work, Haibu Medicine broke through the bottleneck problem of Lacamide research and development technology
At present, there are more than 9 million epilepsy patients in China, accounting for about one-half of the global epilepsy patients. Lacamide is a new type of anti-epileptic drug, which was first marketed in Europe, the United States and Japan, and the technology related to the drug has been protected by patents. The market is monopolized by foreign original manufacturers.
The author was informed that after three years of hard work, the research and development team of Beijing Haibu Pharmaceutical Technology Co., Ltd. broke through the technical bottleneck problem of Lacamide research and development. After testing, the key technical indicators of the drug are superior to the USP and EP standards. This product is expected to be marketed in China in 2020 after being jointly declared with the formulation company.
Domestic genetic sequencing upstream field monopoly shows signs of breaking
Gene sequencing is a novel gene detection technology that can analyze the complete sequence of genes from blood or saliva, predict the possibility of multiple diseases, and the behavioral characteristics and behavior of individuals. The author understands that the upstream of the gene sequencing industry includes sequencer manufacturers, sequencing reagent consumables production companies, and gene capture reagent production companies. For many years, the domestic upstream sector has been monopolized by foreign companies.
However, in recent years, this situation has gradually revealed signs of disintegration. Domestic genetic technology companies have begun to emerge and independently developed genetic core technologies that rival those of foreign countries. For example, Lianchuan Biotech's one-step capture technology is a multiplex PCR-based targeted library preparation technology that takes only a few minutes to complete the process from specific target sequence capture to high-uniformity sequencing library preparation. This technology not only breaks the situation of foreign monopoly, but also provides reference for the research and development of other enterprises.
Good supplier for women bath robe, waterproof dry robe, customized logo bath robe, adult bath robe,kids bath robe, safety jacket, winter jacket, waterproof dry robe and etc.
Features:
1. We are factory directly supplier
2. support customized logo
3. support delivery by sea, by air
Women Bath Robe,Cotton High Quality Hooded Surf Poncho,Women Hotel Bath Robe,Women Bath Robe For Sale
Suzhou Golden Gamrnet MFG Co.,Ltd , https://www.svchangerobe.com